Alvogen and Prestige shake hands on European trastuzumab deal

10 July 2018

Privately-owned US pharma company Alvogen and Prestige BioPharma have announced a commercialization partnership for the latter company's trastuzumab biosimilar in central and eastern Europe (CEE).

Hervelous, as the Singapore firm's biosimilar is known, is an approximation of Roche's Herceptin and is generally used to treat breast and gastroenterological cancers.

Lisa Park, chief executive of Prestige, said: "We are pleased to partner with Alvogen to commercialize our lead biosimilar program in CEE. It is an important step towards our mission to become a leading global biosimilars and biopharmaceuticals development company."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK